期刊文献+

钠/碘转运体在不同甲状腺组织中的表达 被引量:1

Expression of sodium/iodide symporter in different thyroid tissue
下载PDF
导出
摘要 目的:检测钠/碘转运体(sodium/iodide symporter,NIS)在不同甲状腺组织中的表达以及在甲状腺乳头状癌中的分布。方法:选取正常甲状腺组织16例、结节性甲状腺肿组织14例、甲状腺乳头状癌23例,运用蛋白免疫印迹(Western blot)技术检测NIS的表达,并分开提取甲状腺乳头状癌胞浆、胞膜蛋白,分析NIS在甲状腺乳头状癌组织中的分布情况。结果:乳头状癌组、结节性甲状腺肿组NIS表达与正常组相比增高,差异有统计学意义(P<0.05);23例乳头状癌中,21例表达于胞浆,仅10例在胞膜上检测到,阳性率分别为91.3%和43.5%,两者差异有统计学意义(P<0.01);10例胞浆、胞膜均阳性者胞浆组NIS表达高于胞膜组,差异有统计学意义(P<0.01)。结论:在甲状腺乳头状癌、结节性甲状腺肿中NIS表达增高,但是在甲状腺乳头状癌中NIS主要表达在细胞浆中,而非细胞膜上。 Objective: To detect the expression of sodium/iodide symporter(NIS)in different thy-roid tissue,and the distribution of NIS in papillary thyroid carcinoma.Methods: sixteen cases of normal thyroid tissue,14 cases of nodular goiter and 23 cases of papillary thyroid carcinoma were selected,Western blot technique were used to detecte NIS expression in various tissues.Then,cytoplasm and membrane proteins of papillary thyroid carcinoma were extracted separately to analysis the distribution of NIS in papillary thyroid cancer.Results: The expression of NIS in PTC and NG was higher than that in NT.Difference between experimental groups was significant(P 0.05);21 cases expressed in the cytoplasm in 23 cases of PTC,only 10 cases was detected in the membrane,the positive rate was 91.3% and 43.5%,the difference was statistically significant(P 0.01).The expression of the NIS in cytoplasm was higher than that in membrane in 10 cases of positive in cytoplasm and membrane,the difference was statistically significant(P 0.01).Conclusion: The NIS proteins in PTC and NG are over-expressed,but in PTC the NIS is mostly expressed in the cytoplasm rather than in the functional membrane.
出处 《温州医学院学报》 CAS 2011年第4期321-323,共3页 Journal of Wenzhou Medical College
基金 温州市科技局科研基金资助项目(Y20090094)
关键词 钠碘转运体 蛋白免疫印迹 甲状腺乳头状癌 sodium/iodide symporter Western blot papillary thyroid carcinoma
  • 相关文献

参考文献11

  • 1Riesco-Eizaguirre G,Santisteban P.A perspective view of sodium/iodide symporter research and its clinical implications [J].Eur J Endocrinol,2006,155(4):495-512.
  • 2余永利,罗全勇,陈立波,罗琼,丁颖,陆汉魁,朱瑞森,马寄晓.分化型甲状腺癌术后~131Ⅰ治疗生存率分析[J].中华核医学杂志,2006,26(5):261-263. 被引量:21
  • 3肖晨,沈美萍,杨民.钠/碘转运体在甲状腺乳头状癌的表达和分布[J].南京医科大学学报(自然科学版),2008,28(8):1027-1030. 被引量:2
  • 4Tonacchera M,Viaeava EAgretti Eet al. Benign nonfun- ctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein[J].J Clin Endocrinol Metab,2002,87(1):352-357.
  • 5Postiglione MEParlato R,Rodriguez-Mallon A,et al.Role of the thyroidstimulating hormone receptor signaling in development and differentiation of the thyroid gland[J].Proc Natl Acad Sci USA,2002,99(24): 15462-15467.
  • 6Park HJ,Kim JY,Park KY,et al.Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid earcinoma[J].Thyroid,2000,10(3):211- 217.
  • 7Dohan O,Baloch Z,Banrevi Z,et al.Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter(NIS)in a large sampling of thyroid cancer cases[J].J Clin Endocrinol Metab,2001,86(6):2697-2700.
  • 8Ajjan RA,Kamaruddin NA,Crisp M,et al.Regulation and tissue distribution of the human sodium iodide symporter gene[J].Clin Endocrinol, 1998,49(4):517-523.
  • 9Zarnegar R,Brunaud L,Kanauchi H,et al.Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A,a histone deacetylase inhibitor[J].Surgery,2002,132(6):984-990.
  • 10Smit JWA,Elst JPS,Karperien M,et al.Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line[J].Thyroid,2000,10(11):939- 943.

二级参考文献23

  • 1刘超,李倩,段宇,覃又文,刘翠萍,武晓泓,蒋须勤.维甲酸对甲状腺癌细胞钠/碘转运体基因的调节作用[J].中华内分泌代谢杂志,2004,20(4):302-303. 被引量:3
  • 2刘跃武,刘洪沨,孙永亮,李小毅,高维生.甲状腺癌UICC分期第五版与第六版的差异及其对预后评估的准确性比较[J].外科理论与实践,2007,12(2):163-165. 被引量:8
  • 3Kouvaraki MA,Shapiro SE,Lee JE,et al.Surgical management of thyroid carcinoma.J Natl Compr Canc Netw,2005,3:458-466.
  • 4Mazzaferri EL,Kloos RT.Current approaches to primary therapy for papillary and follicular thyroid cancer.J Clin Endocrinol Metab,2001,86:1447-1463.
  • 5Hay ID,Thompson GB,Grant CS,et al.Papillary thyroid carcinoma managed at the Mayo Clinic during six decades(1940-1999):temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.World J Surg,2002,26:879-885.
  • 6Derey TW,Paul GG.Role of 131I in the treatment of well differentiated thyroid cancer.J Gurg Oncol,2005,89:114-121.
  • 7Parthasarathy KL,Crawford ES.Treatment of thyroid carcinoma:emphasis on high-dose 131I outpatient therapy.J Nucl Med Technol,2002,30:165-171.
  • 8Yamashita HM.Locally recurrent thyroid carcinoma.In:Noguchi OHCaS,eds.Thyroid cancer:diagnosis and treatment.St.Louis:Quality Medical Publishing,Inc,2000.312-321
  • 9Sophie L,Carole R,Eric B,et al.Prognosis factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.J Clin Endocrinol Metab,2005,90:1210-1215.
  • 10Liu JD,Hsieh SH,Chang HY,et al.Outcome after treatment for papillary thyroid cancer.Head Neck,2001,23:140-146.

共引文献21

同被引文献26

  • 1聂秀玲,孙云,李兰英,陈祖培.急性碘过量时FRTL细胞钠碘转运体表达的变化[J].中华内分泌代谢杂志,2006,22(4):386-387. 被引量:2
  • 2满娜,关海霞,单忠艳,李玉姝,范晨玲,国秀娟,陈威,佟雅洁,崇巍,毛金媛,滕卫平.慢性碘过量对大鼠甲状腺功能及甲状腺过氧化物酶活性和钠碘同向转运体表达的影响[J].中华医学杂志,2006,86(48):3420-3424. 被引量:17
  • 3Oneal M J, Trujillo MA, Davydova J, et al. Effect of increased vi- ral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium i- odide symporter [ J ]. Cancer Gene Ther,2013,20 ( 3 ) : 195-200.
  • 4So Y, Lee YJ, Lee WW, et al. Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene [ J ]. Oncol Rep, 2013,29 ( 4 ) : 1666 -1670.
  • 5Sue M, Akama T, Kawashima A, et al. Propylthiouracil increases sodium/iodide symporter gene expression and iodide uptake in rat thyroid cells in the absence of TSH [ J ]. Thyroid, 2012,22 ( 8 ) : 844-852.
  • 6Passon N, Puppin C, Lavarone E, et al. Cyclic AMP-response ele- ment modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells [ J ]. Thyroid, 2012,22 ( 5 ) : 487-493.
  • 7Reddi HV, Madde P, McDonough SJ, et al. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy [ J ]. Cancer Gene Ther,2012,19 (9) :659-665.
  • 8Ferreira AC, Lima LP, Araujo RL, et al. Rapid regulation of thy- roid sodium/iodide symporter activity by thyrotrophin and iodine [ J]. J Endocrinol,2005,184 ( 1 ) :69-76.
  • 9Wang ZF, Liu Q J, Liao SQ, et al. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma [ J ]. Tumori, 2011,97 ( 4 ) : 540-546.
  • 10Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF (V600E) and its relationship with sodium iodide symporter in clas- sic variant of papillary thyroid carcinomas [ J ]. Clin Lab, 2012,58 (9) :919-926.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部